Company & Sponsor Intelligence
Abbott
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials5
Recruiting0
Completed4
Countries1
Therapeutic footprint
adhdalzheimersepilepsyschizophrenia
Indexed studies
NCT00102713A Study for Treatment of Partial Seizures in Children
epilepsy · United StatesPHASE3
epilepsy · United StatesPHASE3
NCT00412620An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia
schizophrenia · United StatesPHASE2
schizophrenia · United StatesPHASE2
NCT00646711Pediatric Switch Study for Children and Adolescent Patients With Epilepsy
epilepsy · United StatesPHASE2
epilepsy · United StatesPHASE2
NCT01482845A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease
alzheimers · United StatesPHASE1
alzheimers · United StatesPHASE1
NCT00429091A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
adhd · United StatesPHASE2
adhd · United StatesPHASE2
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →